inVibe’s Labs Introduces TrialPulse
inVibe’s Labs introduces TrialPulse, a technology platform that helps integrate patient insights within the drug development process.
TrialPulse brings patient insights to clinical teams across six important areas, including the patient experience, disease burden, unmet needs, trial design, recruitment, and retention optimization. The innovative market research platform works by virtually recruiting a sample of real patients similar to the study's inclusion/exclusion criteria, then providing them with relevant stimuli (e.g., protocol summaries, e-consent forms, recruitment materials), and prompting them to provide candid feedback via inVibe's proprietary automated voice response (AVR) interview platform.
TrialPulse works by collecting all of the patient voice data, then analyzing it with a combination of human linguistic expertise and advanced machine learning technology, explained by this video. The interactive, searchable, filterable online portal enables our clients to listen to the actual voice responses, share audio clips with other team members and researchers, and/or simply review the high-level executive summary and visual reports created by inVibe analysts.
More on TrailPulse
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
